+

PE20060317A1 - Derivados de xantina como agonistas selectivos del receptor de acido nicotinico - Google Patents

Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Info

Publication number
PE20060317A1
PE20060317A1 PE2005000170A PE2005000170A PE20060317A1 PE 20060317 A1 PE20060317 A1 PE 20060317A1 PE 2005000170 A PE2005000170 A PE 2005000170A PE 2005000170 A PE2005000170 A PE 2005000170A PE 20060317 A1 PE20060317 A1 PE 20060317A1
Authority
PE
Peru
Prior art keywords
nicotinic acid
acid receptor
selective agonists
alkyl
diona
Prior art date
Application number
PE2005000170A
Other languages
English (en)
Inventor
Ivan Leo Pinto
Shahzad Sharooq Rahman
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060317A1 publication Critical patent/PE20060317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 H, ALQUILO C1-C4 SUSTITUIDO O NO POR CN, CF3; R2 ES ALQUILO C3-C10, ALQUILO C1-C10 SUSTITUIDO CON 1 O MAS GRUPOS DE F, CN, ENTRE OTROS; R3 ES HALOGENO, CN. SON COMPUESTOS PREFERIDOS: 8-CLORO-3-(4-PENTEN-1-IL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; (8-CLORO-2,6-DIOXO-1,2,6,7-TETRAHIDRO-3H-PRIN-3-IL)ACETONITRILO; 8-CLORO-3-(4,4,4-TRIFLUOROBUTIL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR DE ACIDO NICOTINICO HM74A UTILES EN ENFERMEDADES DEL METABOLISMO DE LIPIDOS, INSUFICIENCIA CARDIACA, ARTERIOSCLEROSIS, TROMBOSIS, ANGINA, ENTRE OTROS
PE2005000170A 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico PE20060317A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds

Publications (1)

Publication Number Publication Date
PE20060317A1 true PE20060317A1 (es) 2006-06-22

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000170A PE20060317A1 (es) 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Country Status (26)

Country Link
US (5) US7713982B2 (es)
EP (1) EP1781657B1 (es)
JP (2) JP5001012B2 (es)
KR (1) KR101100601B1 (es)
CN (2) CN101103030B (es)
AR (1) AR047669A1 (es)
AU (1) AU2005212816C1 (es)
BR (1) BRPI0507604A (es)
CA (1) CA2556073C (es)
CY (1) CY1114022T1 (es)
DK (1) DK1781657T3 (es)
ES (1) ES2406732T3 (es)
HK (1) HK1104530A1 (es)
HR (1) HRP20130406T1 (es)
IL (1) IL177051A (es)
MA (1) MA28357A1 (es)
MY (1) MY148937A (es)
NO (1) NO337281B1 (es)
NZ (1) NZ548496A (es)
PE (1) PE20060317A1 (es)
PL (1) PL1781657T3 (es)
PT (1) PT1781657E (es)
SG (1) SG157242A1 (es)
SI (1) SI1781657T1 (es)
TW (1) TWI350289B (es)
WO (1) WO2005077950A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4975739B2 (ja) 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
CN101193853B (zh) 2005-06-14 2011-11-23 霍夫曼-拉罗奇有限公司 邻氨基苯甲酸衍生物
DK1901731T3 (da) 2005-06-28 2011-06-14 Merck Sharp & Dohme Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
KR20080038396A (ko) * 2005-08-10 2008-05-06 스미스클라인 비참 코포레이션 선택적 ｈｍ７４ａ 작동제로서의 크산틴 유도체
EP1976854A2 (en) * 2006-01-20 2008-10-08 Shering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia
WO2007134986A1 (en) * 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
BRPI0713619A2 (pt) 2006-06-23 2013-01-15 Incyte Corp composto ou prà-droga ou sal farmaceuticamente aceitÁvel do mesmo, composiÇço, e, uso do composto.
EP2049544B9 (en) * 2006-06-23 2011-07-20 Incyte Corporation Purinone derivatives as hm74a agonists
MX2009010218A (es) 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
EA020037B1 (ru) * 2008-12-08 2014-08-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные ксантина
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
PL3251675T3 (pl) * 2015-01-30 2021-11-02 Shanton Pharma Pte. Ltd. Zapobieganie i leczenie chorobom moczowym i dnie moczanowej
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
BR112019014270B1 (pt) 2017-01-10 2023-12-26 Bayer Cropscience Aktiengesellschaft Derivados de heterociclo, seus usos, formulação agroquímica, e método para controlar pragas animais
CN114727983A (zh) * 2019-09-25 2022-07-08 金翅雀生物公司 黄嘌呤cb1抑制剂
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用
WO2024179463A1 (zh) * 2023-02-27 2024-09-06 珊顿医药科技新加坡公司 化合物8-氯-3-戊基-3,7-二氢-1h-嘌呤-2,6-二酮的晶型及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
DE69332634T2 (de) 1992-03-04 2003-05-08 Cell Therapeutics, Inc. Enantiomere hydroxylierte xanthinverbindungen
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) * 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5780476A (en) * 1992-11-16 1998-07-14 Cell Therapeutics, Inc. Hydroxyl-containing xanthine compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
AU1967495A (en) 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
US6878715B1 (en) * 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US6103730A (en) * 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
DE60024604T2 (de) 1999-04-09 2006-08-24 Cell Therapeutics, Inc., Seattle Xanthinderivate und analoge als zellsignalisierung inhibitoren
US20030207901A1 (en) * 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
CA2383351C (en) * 1999-08-31 2005-11-01 Vanderbilt University Xanthine derivatives as selective antagonists of a2b adenosine receptors
AU2001276023A1 (en) * 2000-07-21 2002-02-05 Mark B Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
WO2002024194A2 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PT1368349E (pt) * 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
WO2002084298A2 (en) 2001-04-11 2002-10-24 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
CN101103030B (zh) * 2004-02-14 2010-10-13 史密丝克莱恩比彻姆公司 具有hm74a受体活性的药物
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
KR20080038396A (ko) * 2005-08-10 2008-05-06 스미스클라인 비참 코포레이션 선택적 ｈｍ７４ａ 작동제로서의 크산틴 유도체
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
EA020037B1 (ru) * 2008-12-08 2014-08-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные ксантина
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
MA28357A1 (fr) 2006-12-01
AU2005212816C1 (en) 2010-03-04
CA2556073A1 (en) 2005-08-25
JP5001012B2 (ja) 2012-08-15
ES2406732T3 (es) 2013-06-07
CN101103030A (zh) 2008-01-09
TW200536537A (en) 2005-11-16
AU2005212816A1 (en) 2005-08-25
US8268839B2 (en) 2012-09-18
BRPI0507604A (pt) 2007-07-03
PT1781657E (pt) 2013-05-23
KR101100601B1 (ko) 2011-12-29
HK1104530A1 (en) 2008-01-18
SG157242A1 (en) 2009-12-29
DK1781657T3 (da) 2013-06-10
MY148937A (en) 2013-06-14
CY1114022T1 (el) 2016-07-27
EP1781657B1 (en) 2013-03-27
NZ548496A (en) 2010-02-26
WO2005077950A2 (en) 2005-08-25
KR20060126772A (ko) 2006-12-08
CN101863888B (zh) 2012-07-18
JP2008120831A (ja) 2008-05-29
PL1781657T3 (pl) 2013-08-30
IL177051A (en) 2013-01-31
US8394808B2 (en) 2013-03-12
NO337281B1 (no) 2016-02-29
WO2005077950A3 (en) 2007-04-19
TWI350289B (en) 2011-10-11
NO20064151L (no) 2006-11-06
JP2007522176A (ja) 2007-08-09
IL177051A0 (en) 2006-12-10
JP5020848B2 (ja) 2012-09-05
CN101103030B (zh) 2010-10-13
US20130150383A1 (en) 2013-06-13
CA2556073C (en) 2012-01-10
AR047669A1 (es) 2006-02-01
US20150080418A1 (en) 2015-03-19
CN101863888A (zh) 2010-10-20
US7713982B2 (en) 2010-05-11
HRP20130406T1 (hr) 2013-06-30
SI1781657T1 (sl) 2013-07-31
EP1781657A2 (en) 2007-05-09
US20100160354A1 (en) 2010-06-24
US20100010021A1 (en) 2010-01-14
US20070135456A1 (en) 2007-06-14
AU2005212816B2 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
PE20060317A1 (es) Derivados de xantina como agonistas selectivos del receptor de acido nicotinico
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
Patel et al. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor
Innocenti et al. Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure–activity relationship, structural biology, and cellular activity
EA200500881A1 (ru) N-арилсульфонил-3-замещенные индолы, обладающие афинностью к серотониновому рецептору, способ их получения и содержащая их фармацевтическая композиция
PE20140630A1 (es) Derivados de acido 3-fenilpropionico ramificados y su uso
PE20060210A1 (es) 8-[3-amino-piperidin-1-il]-xantinas como inhibidores de dpp-iv
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
AR072557A1 (es) Proceso para preparar composiciones de medicamentos que contienen dabigatran
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
CY1114092T1 (el) Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης
PE20080421A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
PE20070419A1 (es) Derivados de benzoquinazolina
EA200601364A1 (ru) Производные хинолина и их применение в качестве ингибиторов микобактерий
EA200101107A1 (ru) Пуриновые производные
UY27965A1 (es) Derivados heterocíclicos
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
PE20070219A1 (es) 8-(3-amino-piperidin-1-il)-xantinas, su preparacion y su uso como medicamentos
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
ECSP067079A (es) Derivados de ácido carboxílico de bencimidazolona
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales
PE20100093A1 (es) Derivados de acetileno
PE20210856A1 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载